Abstract
Pigmented villonodular synovitis is a chronic inflammatory disease progressing with histological villonodular hyperplasia in synovium, fibrosis and accumulation of hemosiderin. Knee joint is frequently involved leading to severe joint damage and disability in untreated cases. Treatment options include surgical intervention or radio-synovectomy with intraarticular yttrium-90. The case presented here includes significant clinical and radiological disease regression after intraarticular adalimumab in a patient diagnosed with radiologically and histologically confirmed pigmented villonodular synovitis who did not consent to surgical intervention.
This is a preview of subscription content, log in via an institution to check access.
References
Ofluoglu O (2006) Pigmented villonodular synovitis. Orthop Clin North Am 37:3–33
Byers PD, Cotton RE, Deacon OW, Lowy M, Newman PH, Sissons HA et al (1968) The diagnosis and treatment of pigmented villonodular synovitis. J Bone Jt Surg Br 50:290–305
Akgun I, Ogut T, Kesmezacar H, Dervisoglu S (2003) Localized pigmented villonodular synovitis of the knee. Orthopedics 26:1131–1135
Flandry F, Hughston JC, McCann SB, Kurtz DM (1994) Diagnostic features of diffuse pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 298:212–220
Jaffe HL, Lichtenstein L, Sutro CJ (1941) Pigmented villonodularis synovitis: bursitis and tenosynovitis. Arch Pathol 31:731–765
Aigner T, Oehler S, Niedobitek HG, Fassbender G, Kirchner T (1998) Iron deposits, cell populations and proliferative activity in pigmented villonodular synovitis of the knee joint. Verh Dtsch Ges Pathol 82:327–331
Neale SD, Kristelly R, Gundle R, Quinn JM, Athanasou NA (1997) Giant cells in pigmented villonodular synovitis express an osteoclast phenotype. J Clin Pathol 50:605–608
O’Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG (1998) Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J 18:26–34
Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T et al (2003) Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 34:65–73
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259
Berger I, Weckauf H, Helmchen B, Ehemann V, Penzel R, Fink B et al (2005) Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathology 46:490–497
Yudoh K, Matsuno H, Nezuka T, Kimura T (1999) Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum 42:669–677
Kroot EJ, Kraan MC, Smeets TJ, Maas M, Tak PP, Wouters JM (2005) Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 64:497–499
Fiocco U, Sfriso P, Oliviero F, Sovran F, Scagliori E, Pagnin E, Vezzù M, Cozzi L, Botsios C, Nardacchione N, Di Maggio A, Rubaltelli L, Giacometti C, Calabrese F, Todesco S (2006) Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis. Reumatismo 58(4):268–274
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobak, S. Intraarticular adalimumab in a patient with pigmented villonodular synovitis. Rheumatol Int 31, 251–254 (2011). https://doi.org/10.1007/s00296-009-1185-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1185-z